Medications for bipolar disorder
What medications are used across mania, bipolar depression, and maintenance, and where the pitfalls sit.
First-line options
Acute mania
For acute mania, the options are lithium, valproate, and the atypical antipsychotics. Any of them can work as monotherapy for less severe presentations, and combination (lithium or valproate plus an atypical) is standard for more severe or psychotic mania.
Lithium at target level 0.8 to 1.2 mEq/L is the classic mood stabilizer for acute mania. It works, and it carries the additional benefit of reducing suicide risk. Onset in mania is 1 to 2 weeks, so it's usually paired with an antipsychotic for faster control.
Valproate (divalproex, valproic acid) at target level 50 to 125 mcg/mL is roughly comparable to lithium for acute mania and slightly favored for mixed features and rapid cycling. It's teratogenic (neural tube defects, cognitive effects in offspring), so it's generally avoided in people of reproductive age unless there's a plan around contraception.
The atypical antipsychotics with FDA approval for acute mania include olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, cariprazine, and asenapine. Any of them can control mania quickly. Olanzapine is fast but hard on weight and metabolism. Quetiapine is sedating, which helps in the hospital and matters less later. Aripiprazole is metabolically kinder and available as a long-acting injection. Cariprazine has partial agonist activity at dopamine receptors that resembles aripiprazole. See the antipsychotic class page for the fuller comparison.
Haloperidol still works and is used in acute settings for rapid control, but atypicals are the standard maintenance choice afterward.
Bipolar depression
Bipolar depression is where the algorithm diverges most sharply from unipolar depression. The medications with FDA approval for bipolar depression are:
- Lurasidone monotherapy or as add-on to lithium or valproate. Metabolically kinder than most of the class. Must be taken with 350 calories of food to be absorbed.
- Quetiapine monotherapy at 300 mg. Sedating.
- Cariprazine monotherapy at 1.5 to 3 mg.
- Olanzapine-fluoxetine combination (Symbyax). Works, but the olanzapine metabolic burden is real.
Beyond those, lithium has evidence for bipolar depression, particularly for maintenance and suicide reduction. Lamotrigine has evidence more for depression prevention in maintenance than for acute depression, though it's often started during a depressive episode with the eye toward maintenance.
Antidepressants (SSRIs, SNRIs, bupropion) are used in bipolar depression, but always with a mood stabilizer on board, and the evidence is more mixed than most patients expect. Bupropion tends to be the more commonly picked antidepressant in bipolar because of lower switch risk, but the whole category carries some risk of triggering mania, mixed states, or cycle acceleration.
Maintenance
Maintenance is the phase most people spend most of their time in, and it's the phase where the choice matters most for the long haul.
Lithium is the classic maintenance option. It reduces manic recurrence, depressive recurrence, and suicide risk. The last of those is real and unique to lithium among the mood stabilizers. Target level for maintenance is 0.6 to 0.8 mEq/L, sometimes 0.8 to 1.0.
Lamotrigine is the maintenance option specifically for depression prevention. It doesn't do much for acute mania, so it's often paired with another agent for mania coverage. The Stevens-Johnson rash risk means titration has to be slow (starting at 25 mg for 2 weeks), and any rash needs to be evaluated seriously.
Valproate is used for maintenance, especially in patients with mixed features or rapid cycling.
Atypical antipsychotics with maintenance approval include olanzapine, quetiapine, aripiprazole, risperidone LAI, and asenapine. LAI options are worth considering when adherence is a chronic problem.
See the mood stabilizer class page for the fuller picture.
Second-line and augmentation
Combination therapy
Most patients with bipolar I end up on combination therapy at some point. Lithium plus an atypical, valproate plus an atypical, lithium plus lamotrigine (mania covered by lithium, depression covered by lamotrigine), and so on. The rationale is that no single agent covers all three phases well.
Anticonvulsant options beyond valproate and lamotrigine
Carbamazepine is FDA-approved for acute mania. The CYP interactions (it's a potent 3A4 inducer) and hematologic risks (agranulocytosis, aplastic anemia) keep it off first-line lists, but it's still useful in patients who haven't tolerated other options. Oxcarbazepine is the metabolite of carbamazepine with fewer interactions but weaker evidence in bipolar.
Topiramate is used for weight neutrality or weight loss and as an anticonvulsant, but the evidence for mood stabilization is thin. It's usually an adjunct rather than a mainstay.
Adjunctive antidepressants (with a stabilizer)
When bipolar depression doesn't respond to the FDA-approved options, adding an antidepressant to a mood stabilizer is a common next step. The consensus is bupropion or an SSRI over an SNRI or TCA, and always alongside a stabilizer. Antidepressant monotherapy in bipolar depression is generally avoided.
Other options
Pramipexole has some evidence for bipolar depression at low doses (off-label). Modafinil or armodafinil as augmentation for bipolar depression with prominent fatigue has small trial evidence. Neither is standard.
When to consider a different approach
Rapid cycling
Rapid cycling (four or more mood episodes in 12 months) responds less well to lithium alone. Valproate and lamotrigine tend to do better. Antidepressants can accelerate cycling, so they're usually removed if a patient becomes rapid-cycling. Atypicals as maintenance are reasonable.
Mixed features
Mixed features (depression with agitation, or mania with dysphoria) also do less well with lithium alone. Valproate and second-generation antipsychotics (cariprazine has some data specifically for mixed states) are the leaning.
Treatment-resistant bipolar depression
If FDA-approved options have failed, ECT is highly effective for bipolar depression, particularly with psychotic features or suicidal ideation. Ketamine and esketamine have data in bipolar depression and are used off-label with a stabilizer on board. TMS is FDA-cleared for MDD but has emerging evidence in bipolar depression.
Treatment-resistant mania
Clozapine is used in treatment-resistant mania, particularly with psychotic features. ECT works. Combination lithium plus valproate plus an atypical is common in refractory cases.
Special considerations
Antidepressants: proceed with caution
The single most important pattern in bipolar treatment: antidepressant monotherapy without a mood stabilizer risks switching a patient into mania or accelerating cycling. Screening for a bipolar history before starting an antidepressant for depression is worth doing routinely. Past manic or hypomanic episodes, family history of bipolar, early onset depression, and antidepressant-induced activation or mania are all signals.
If a bipolar patient does need an antidepressant, bupropion tends to carry a lower switch risk than SNRIs or TCAs. It's always paired with a mood stabilizer.
Pregnancy
Lithium in the first trimester carries a small increased risk of Ebstein's anomaly. Valproate is teratogenic (neural tube defects, cognitive impairment) and generally avoided in people who could become pregnant. Lamotrigine is the safest of the mood stabilizers in pregnancy but does need dose adjustment during pregnancy because clearance increases. See the pregnancy safety reference.
Older adults
Lithium levels rise as renal function declines. Older adults are more sensitive to lithium toxicity at lower levels. Target 0.4 to 0.6 mEq/L is often adequate. Atypical antipsychotics carry the mortality boxed warning in dementia populations. See Beers Criteria for psychiatric medications.
Renal and hepatic function
Lithium is excreted renally, so kidney function matters. Valproate and carbamazepine are hepatically metabolized and can raise LFTs. Baseline labs and periodic monitoring are standard. See renal dosing and hepatic dosing references.
Bipolar with comorbid anxiety
Anxiety is common in bipolar and often persists between mood episodes. Quetiapine has anxiolytic activity. Lurasidone is reasonably calming. Lamotrigine can help with the anxiety that comes along with bipolar depression. Benzodiazepines have a role for acute anxiety in bipolar, though with the usual dependence and cognitive concerns. Gabapentin off-label is sometimes used, though the evidence in bipolar anxiety is thin.
Bipolar with comorbid substance use
Substance use is common and complicates every decision. Alcohol worsens sleep, worsens mood, and interacts with lithium (dehydration risk). Stimulants (from ADHD treatment or misuse) can precipitate manic episodes. Valproate over lithium is often favored when substance use is active, mainly because valproate is more forgiving of missed doses and dehydration.
What tips the choice
The framework: figure out what phase the patient is in now, and pick an agent that covers that phase and won't destabilize the phases it doesn't cover.
- Acute mania, first episode: lithium or valproate plus an atypical. Add whatever gives the fastest control that's compatible with maintenance.
- Acute bipolar depression: quetiapine, lurasidone, cariprazine, or olanzapine-fluoxetine. Lithium or lamotrigine as background stabilizer if not already on one.
- Maintenance with predominantly manic history: lithium or valproate, with or without an atypical.
- Maintenance with predominantly depressive history: lamotrigine, plus something that covers mania (lithium is the common pairing).
- Rapid cycling: valproate or lamotrigine, avoid antidepressants.
- Mixed features: valproate or cariprazine.
- Mixed features with prominent depression: cariprazine or lurasidone.
- Suicidal ideation history: lithium if tolerable. It's the only mood stabilizer with anti-suicide evidence.
- Reproductive potential: avoid valproate. Favor lamotrigine or lithium with informed discussion.
- Poor adherence: LAI atypical (aripiprazole Maintena, Abilify Asimtufii, risperidone Consta, Uzedy, paliperidone LAIs).
- Metabolic risk: lurasidone, aripiprazole, cariprazine over olanzapine or quetiapine.
The larger point is that bipolar treatment is a long-term project. What works during a hospitalization for mania often isn't what someone wants to be on for the next twenty years. Planning the transition is part of the treatment.
Common questions
Can antidepressants make bipolar disorder worse? Yes, sometimes. Antidepressant monotherapy without a mood stabilizer can trigger a switch into mania or hypomania or accelerate cycling. This is why screening for a bipolar history before starting an antidepressant matters, and why in known bipolar disorder, antidepressants (if used at all) are paired with a mood stabilizer.
How is bipolar depression different from regular depression to treat? The agents that work best for unipolar depression (SSRIs, SNRIs) don't work as reliably in bipolar depression, and they carry switch risk. The FDA-approved options for bipolar depression are lurasidone, quetiapine, cariprazine, and olanzapine-fluoxetine. Lithium and lamotrigine also have a role. The framework is different.
Do I have to be on lithium forever? No, but if lithium has stabilized your mood, coming off it is a decision that should be made carefully and gradually. Abrupt discontinuation of lithium carries a real risk of manic relapse, and there's some evidence that response to lithium may be reduced if it's restarted after discontinuation. If lithium is working, most people stay on it long-term.
What about lamotrigine and rash? The Stevens-Johnson syndrome risk with lamotrigine is real but small (roughly 1 in 1000 for serious rash in adults, more common in children). Slow titration (25 mg for 2 weeks, then 50 mg for 2 weeks, then increase) reduces the risk. Any rash within the first 2 to 8 weeks needs to be evaluated. If lamotrigine is stopped for more than 5 days, restarting requires the full slow titration again.
What happens if I miss a dose? For lithium, one missed dose isn't a crisis, but chronic missed doses lower levels and lose the therapeutic effect. For lamotrigine, missed doses can affect seizure threshold if it's being used for seizures, and if you miss more than 5 days you have to restart the titration. For atypicals, one missed dose isn't a crisis, but the LAI options exist specifically for patients who have trouble with daily dosing.
Sources
This guide draws on current prescribing information, treatment guidelines, and public health references. It is reviewed for clinical accuracy and updated as guidance changes.
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder.
- Yatham LN et al. CANMAT and ISBD guidelines for the management of patients with bipolar disorder.
- National Institute of Mental Health. Bipolar disorder.
- MedlinePlus, U.S. National Library of Medicine.
THE KNOWLEDGE PATH
Walk this topic outward.
- GUIDE Medications for bipolar disorder (current)
- CLASS SSRIs
- MEDICATION Sertraline (Zoloft)
- CONDITION Major Depressive Disorder (on Shrinkopedia)
- CARE Consider depression evaluation at shrinkMD
The Knowledge Path is a curated walk. Every step is one decision away from the next.
Managing a medication needs a prescriber
Any psychiatric medication has to be started and adjusted by a clinician who can follow you over time. If you don't have a prescriber, our guides section explains the options, including in-person care and telepsychiatry, and how to choose between them.